Mecasermin

Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[1][2][3]

Mecasermin
Clinical data
Trade namesIncrelex
Other namesFK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Subcutaneous injection
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Elimination half-life5.8 hours[1]
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    ChEMBL
    Chemical and physical data
    FormulaC331H512N94O101S7
    Molar mass7648.67 g/mol g·mol−1
     NY (what is this?)  (verify)

    Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[1]

    A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[4] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[4]

    References
    1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021839s016lbl.pdf
    2. Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and Clinical Risk Management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
    3. "Increlex". Drugs.com. Retrieved 10 January 2010.
    4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021884s001lbl.pdf



    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.